Cohera Medical's surgical sealants attracted a $26.3M Series D

Cohera Medical can celebrate now that it has $26.3 million in Series D financing to fuel regulatory approvals for its surgical adhesives and sealants. That's a jump of $9.3 million more from initial funding the Pittsburgh company nailed down for the round last February.

Execs aren't offering details about the investors. But the company is fast at work gaining approvals for its main products, and the cash is intended to propel it through the regulatory finish line in both the U.S. and Europe.

At the end of 2013, Cohera completed its premarket approval application for its TissuGlu Surgical Adhesive and is waiting to hear from the FDA. TissuGlu already has a CE marking, and the company has sold it to German hospitals and surgeons since 2011. It's designed for abdominal procedures and sticks to tissue flaps during surgery, working to prevent fluid buildup and reduce the need for postoperative draining, the company said.

The Pennsylvania company said it is also pursuing a CE mark for its Sylys surgical sealant, designed specifically to prevent leakage during gastrointestinal procedures. It is a synthetic product designed to protect sutures or staples and help prevent leaks. A human trial completed at the end of 2013 demonstrated the product's safety, according to the company.

Devices that seal surgical incisions are becoming a draw for investors these days. Recently, for example, California's ZipLine Medical raised $4.3 million to advance a marketing plan for its surgical skin-closure device that works like a Band-Aid.

- read the release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.